Raloxifene HCl is a selective estrogen receptor modulator that is marketed as an oral medication under the brand name of Evista. The estrogenic property of Evista affects the formation and breakdown of bones and helps in reducing the loss of bone tissues. This makes it an effective medicine in treating osteoporosis in postmenopausal women. On the other hand the anti-estrogenic properties of this medicine have a pronounced effect in reducing the risk of invasive breast cancer in postmenopausal women suffering from osteoporosis.
For more Visit : http://www.daynighthealthcare247.com/product/generic-evistahttp://www.daynighthealthcare247.com/category/womens-health
